Abstract
Study group consisted of 84 oncological patients with various tumor localization that received chemotherapy with taxanes. Medium follow up was 32.1 +/- 2.1 months. All patients had morphologic verification of the process. Distribution according to tumor localization was as follows: breast cancer--60 (71.4%), ovarian cancer--13 (15.5%), lung cancer--7 (8.3%), other localizations--4 (4.8%). Age varied from 22 to 73 years old. All patients had normal hematological status and survival expectation more than 3 months. Hematological complications were mentioned after the first cycle of chemotherapy in 70% cases.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Breast Neoplasms / drug therapy
-
Caproates
-
Docetaxel
-
Female
-
Fever / etiology
-
Fever / prevention & control
-
Follow-Up Studies
-
Homeostasis / drug effects
-
Humans
-
Imidazoles / administration & dosage
-
Imidazoles / therapeutic use*
-
Lung Neoplasms / drug therapy
-
Male
-
Middle Aged
-
Neoplasms / drug therapy*
-
Neoplasms / pathology
-
Neutropenia / chemically induced*
-
Neutropenia / complications
-
Neutropenia / diagnosis
-
Neutropenia / prevention & control*
-
Ovarian Neoplasms / drug therapy
-
Paclitaxel / adverse effects
-
Prostatic Neoplasms / drug therapy
-
Protective Agents / administration & dosage
-
Protective Agents / therapeutic use*
-
Severity of Illness Index
-
Stomach Neoplasms / drug therapy
-
Taxoids / administration & dosage
-
Taxoids / adverse effects*
-
Tongue Neoplasms / drug therapy
Substances
-
Caproates
-
Imidazoles
-
Protective Agents
-
Taxoids
-
Docetaxel
-
pentanedioic acid imidazolyl ethanamide
-
Paclitaxel